PHARMAESSENTIA ANNOUNCES POSITIVE TOPLINE PHASE 2B DATA FROM EXCEED-ET STUDY EVALUATING ROPEGINTERFERON ALFA-2B-NJFT FOR ESSENTIAL THROMBOCYTHEMIA
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.